Key result
Captopril use was associated with a lower relative risk of developing prostate cancer, whereas no clear association was found for other antihypertensive drugs.
Why the study?
Does captopril or other antihypertensive drugs affect the risk of prostate cancer in male patients aged 50-79 years?
Case-Control
Does captopril or other antihypertensive drugs affect the risk of prostate cancer in male patients aged 50-79 years?
There is no clear association between the use of most antihypertensive drugs and prostate cancer, though captopril users showed a trend toward lower risk that requires further research.
Answers are grounded in this paper and cite their sources.
Should not yet change antihypertensive prescribing; leaves open a potential captopril effect requiring prospective trials.
BACKGROUND: There has been some debate on the existence of an association between hypertension, antihypertensive medications and cancer risk. METHODS: We performed a nested case-control study to assess the association between the risk of prostate cancer and the use of the angiotensin converting enzyme (ACE)-inhibitor captopril, and other antihypertensive drugs. We used data from the General Practice Research Database in UK. RESULTS: We found an incidence rate of prostate cancer of 1.61 per 1,000 person-years among male patients aged 50-79 years old. Patients with a history of benign prostatic hyperplasia and/or prostatism carried a two-fold greater risk of prostate cancer than those without such antecedents. None of the other studied co-morbidities were associated with prostate cancer. We found that users of captopril had a relative risk of 0.7 (95% CI: 0.4-1.2) to develope prostate cancer. None of the other studied individual ACE-inhibitors shared a similar effect with the one observed for captopril. CONCLUSIONS: No clear association was apparent between the use of antihypertensive drugs and prostate cancer. However, specific focus on users of captopril showed a lower risk of subsequent prostate cancer. Further research is needed to explore this association.
No takes yet. Share an insight, caveat, or question.
Ronquist et al. (2003) conducted a case-control in prostate cancer. captopril was evaluated on risk of prostate cancer (RR 0.7, 95% CI 0.4-1.2). Captopril use was associated with a lower relative risk of developing prostate cancer, whereas no clear association was found for other antihypertensive drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: